

Date: December 04, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Disclosure under Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulation, 2011.

Pursuant to the provisions of Regulation 31(1) and 31(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, please find enclosed herewith the disclosure received from Renosen Pharmaceuticals Private Limited, Promoter Group of the Company, in respect of creation of Pledge of 4,00,000 (Four Lakhs) Equity Shares of Senores Pharmaceuticals Limited.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Digitally signed by
Vinay Kumar Mishra
Date: 2025.12.04
15:07:32 +05'30'

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl: As Above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Date: December 04, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES


Sub.: Disclosure as required under Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation, 2011

In pursuance of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”), please find attached disclosure under SAST Regulations for Pledge of 4,00,000 (Four Lakhs) Equity Shares on December 03, 2025 of Senores Pharmaceuticals Limited.

This is for your information and records.

Thanking You.

Yours Faithfully,
For Renosen Pharmaceuticals Private Limited


Swapnil Jatinbhai Shah
Director
DIN: 05259821



CC:
Company Secretary
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One 42,
Opp. Jayantilal Park, Ambali Bopal Road,
Ahmedabad -380054

Enclosure: As above

Renosen Pharmaceuticals Private Limited

(Formerly known as Senores Lifesciences Pvt. Ltd.)

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India.
P: +91 79 2999 9857 | E: info@senorespharma.com | CIN NO: U51909GJ2019PTC108258

Disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


1.	Name of the Target Company	Senores Pharmaceuticals Limited
2.	Names of the stock exchanges where the shares of the target company are listed	BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")
3.	Date of reporting	December 04,2025
4.	Name of the Promoter or PAC on whose shares encumbrance has been created/released/invoked	Renosen Pharmaceuticals Private Limited


5. Details of encumbrance:

[illegible]

Shantaben Babulal Sanghvi	3,28,569	0.7134	-	-									
Remus Pharmaceuticals Limited	32,61,744	7.0825	-	-									

For and on behalf of Renosen Pharmaceuticals Private Limited


Name: Swapnil Jatinbhai Shah
Designation: Director
DIN: 05259821



Date: 04/12/2025

Place: Ahmedabad

**The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.*

*** For example, for the purpose of collateral for loans taken by the company, personal borrowing, third party pledge, etc.*

****This would include name of both the lender and the trustee who may hold shares directly or on behalf of the lender.*